Personalization of Radiotherapy Dose in HPV Positive Oropharynx Cancer Using GARD.

ABSTRACT: A central clinical goal for patients with HPV-positive oropharynx cancer has been to reduce radiation doses while maintaining cure rates. Recent results of Phase 3 prospective trial HN005 demonstrated that RT dose de-escalation can not be safely done based on clinical factors alone. We have previously shown that the genomic adjusted radiation dose (GARD) is predictive of radiation treatment benefit and can be used to guide RT dose selection. We hypothesize that GARD can be used to guide RT dose de-escalation in HPV-positive OPSCC patients. Gene expression was analyzed for 191 formalin-fixed paraffin-embedded samples from HPV-positive OPSCC patients within an international, multi-institutional, prospective/retrospective observational study including patients with AJCC 8th edition stage I-II

SUBMITTER: Ho E 

PROVIDER: S-EPMC10516067 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature